TPO-RA治疗儿童原发免疫性血小板减少症效果与安全性  

Efficacy and safety of thrombopoietin receptor agonists in treatment of children with primary immune thrombocytopenia

作　　者：张茗雪 张磊 梁卉 ZHANG Mingxue;ZHANG Lei;LIANG Hui(Qingdao University Medical College,Qingdao 266073,China)

机构地区：[1]青岛大学医学部,山东青岛266073 [2]青岛市妇女儿童医院血液科

出　　处：《青岛大学学报（医学版）》2024年第5期771-774,共4页Journal of Qingdao University(Medical Sciences)

基　　金：青岛市科技惠民示范引导专项计划(21-1-4-rkjk-18-nsh)。

摘　　要：目的探究血小板生成素受体激动剂(TPO-RA)治疗儿童原发免疫性血小板减少症(ITP)的效果与安全性。方法收集16例经糖皮质激素、免疫球蛋白等一线治疗无效或者病情仍反复,并且口服TPO-RA治疗的ITP病儿的临床资料,监测TPO-RA治疗前后病儿血小板(PLT)计数的变化、出血分级变化以及不良事件发生情况。结果16例ITP病儿用药1、2、3周及1、2、3、4月PLT计数与治疗前比较,差异有统计学意义(Z=2.261~3.408,P<0.05);治疗后出血分级较治疗前有明显改善,差异有显著性(Z=-2.140,P<0.05)。治疗过程中出现的不良反应多为轻中度,病儿均可耐受,无严重不良反应事件。结论TPO-RA治疗儿童ITP效果佳、安全性高,病儿可耐受性强。Objective To investigate the efficacy and safety of thrombopoietin receptor agonists(TPO-RA)in the treatment of children with primary immune thrombocytopenia(ITP).Methods Clinical data were collected from 16 children with ITP who had no response to the first-line treatment including glucocorticoids and immunoglobulin,experienced disease recurrence,and received oral administration of TPO-RA,and they were monitored in terms of platelet count(PLT),bleeding grade,and adverse events before and after treatment.Results All 16 children showed a significant change in PLT after 1,2,and 3 weeks and 1,2,3,and 4 months of administration(Z=2.261 to 3.408,P<0.05),and there was a significant improvement in bleeding grade after treatment(Z=-2.140,P<0.05).Adverse events during treatment were mostly mild or moderate,and the children were to-lerant to these adverse events,with no serious adverse events during treatment.Conclusion TPO-RA has good efficacy,high safety,and good tolerability in children with ITP.

关 键 词：血小板生成素受体激动剂 儿童 紫癜 血小板减少性 特发性 治疗结果 药物相关性副作用和不良反应 

分 类 号：R554.6[医药卫生—血液循环系统疾病]